{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:44:00Z","timestamp":1792511040768,"version":"4.5.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013500","name":"Canadian Cardiovascular Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1\u20133 months) compared to standard DAPT (6\u201312 months) on bleeding and ischemic events in HBR PCI.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1\u20133 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>From 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84\u20131.23), all-cause death (RR 0.92, 95% CI 0.71\u20131.20) or stent thrombosis (RR 1.47, 95% CI 0.73\u20132.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13\u20130.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44\u20130.81), translating to 21 and 34 fewer events, respectively, per 1000 patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In HBR PCI, DAPT for 1\u20133 months compared to 6\u201312 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0291061","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:26:18Z","timestamp":1693589178000},"page":"e0291061","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis"],"prefix":"10.1371","volume":"18","author":[{"given":"Kevin R.","family":"Bainey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Marquis-Gravel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-1790","authenticated-orcid":true,"given":"Blair J.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bewick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-1528","authenticated-orcid":true,"given":"Ricky D.","family":"Turgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"pone.0291061.ref001","first-page":"34","article-title":"2018 Canadian Cardiovascular Society\/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy","author":"SR Mehta","year":"2018","journal-title":"Canadian Journal of Cardiology"},{"key":"pone.0291061.ref002","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.","volume":"389","author":"F Costa","year":"2017","journal-title":"The Lancet"},{"key":"pone.0291061.ref003","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk.","volume":"382","author":"S Windecker","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"pone.0291061.ref004","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2021.08.074","article-title":"Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI","volume":"78","author":"M Valgimigli","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"pone.0291061.ref005","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial","volume":"321","author":"JY Hahn","year":"2019","journal-title":"JAMA"},{"key":"pone.0291061.ref006","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"P Vranckx","year":"2018","journal-title":"The Lancet"},{"key":"pone.0291061.ref007","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"R Mehran","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"pone.0291061.ref008","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial","volume":"323","author":"BK Kim","year":"2020","journal-title":"JAMA"},{"key":"pone.0291061.ref009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of Clopidogrel Monotherapy after 1 to 2 Months of Dual Antiplatelet Therapy with 12 Months of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial","volume":"7","author":"H Watanabe","year":"2022","journal-title":"JAMA Cardiology"},{"key":"pone.0291061.ref010","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.","volume":"321","author":"H Watanabe","year":"2019","journal-title":"JAMA\u2014Journal of the American Medical Association"},{"key":"pone.0291061.ref011","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2020.05.031","article-title":"Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI","volume":"76","author":"G Marquis-Gravel","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"key":"pone.0291061.ref012","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting","volume":"73","author":"F Costa","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"pone.0291061.ref013","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"140","author":"P Urban","year":"2019","journal-title":"Circulation"},{"key":"pone.0291061.ref014","first-page":"366","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","author":"JAC Sterne","year":"2019","journal-title":"The BMJ"},{"key":"pone.0291061.ref015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"H Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"pone.0291061.ref016","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"DE Cutlip","year":"2007","journal-title":"Circulation"},{"key":"pone.0291061.ref017","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2","volume":"137","author":"HM Garcia-Garcia","year":"2018","journal-title":"Consensus Document. Circulation"},{"key":"pone.0291061.ref018","article-title":"Special Report Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium.","author":"R Mehran","year":"2011"},{"key":"pone.0291061.ref019","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.","volume":"385","author":"M Valgimigli","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"pone.0291061.ref020","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jacc.2022.04.065","article-title":"Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy","volume":"80","author":"M Valgimigli","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"key":"pone.0291061.ref021","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/eurheartj\/ehac284","article-title":"Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis","volume":"43","author":"M Valgimigli","year":"2022","journal-title":"European heart journal"},{"key":"pone.0291061.ref022","first-page":"1196","article-title":"Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized","volume":"144","author":"PC Smits","year":"2021","journal-title":"Controlled Trial. Circulation"},{"key":"pone.0291061.ref023","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR","volume":"42","author":"J Escaned","year":"2021","journal-title":"European Heart Journal"},{"key":"pone.0291061.ref024","first-page":"324","article-title":"Ticagrelor Monotherapy After 3-","volume":"52","author":"YJ Lee","year":"2022","journal-title":"Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial. Korean Circulation Journal"},{"key":"pone.0291061.ref025","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1161\/CIRCULATIONAHA.119.043613","article-title":"Very Short Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in Patients with High Bleeding Risk: Insight from the STOPDAPT-2","volume":"140","author":"H Watanabe","year":"2019","journal-title":"Trial. Circulation"},{"key":"pone.0291061.ref026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12928-020-00651-9","article-title":"Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial.","volume":"36","author":"H Watanabe","year":"2021","journal-title":"Cardiovascular intervention and therapeutics"},{"key":"pone.0291061.ref027","first-page":"E012004","article-title":"Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. Circulation","volume":"15","author":"Y Obayashi","year":"2022","journal-title":"Cardiovascular Interventions"},{"key":"pone.0291061.ref028","article-title":"Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis","author":"SU Khan","year":"2020","journal-title":"Circulation"},{"key":"pone.0291061.ref029","doi-asserted-by":"crossref","first-page":"l2222","DOI":"10.1136\/bmj.l2222","article-title":"Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis","volume":"365","author":"S-H-L Yin","year":"2019","journal-title":"BMJ"},{"key":"pone.0291061.ref030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvaa001","article-title":"Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials","volume":"7","author":"S Benenati","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"pone.0291061.ref031","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/ehjcvp\/pvaa127","article-title":"Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis","volume":"8","author":"S Benenati","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"pone.0291061.ref032","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials","volume":"44","author":"F Costa","year":"2023","journal-title":"Eur Heart J"},{"key":"pone.0291061.ref033","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCINTERVENTIONS.111.967083","article-title":"Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials","volume":"5","author":"T Palmerini","year":"2012","journal-title":"Circulation Cardiovascular interventions"},{"key":"pone.0291061.ref034","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.","volume":"397","author":"BK Koo","year":"2021","journal-title":"The Lancet"},{"key":"pone.0291061.ref035","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","author":"M. Gent","year":"1996","journal-title":"Lancet"},{"key":"pone.0291061.ref036","doi-asserted-by":"crossref","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.","author":"T Cuisset","DOI":"10.1093\/eurheartj\/ehx175"},{"key":"pone.0291061.ref037","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.","volume":"398","author":"CJ Kim","year":"2021","journal-title":"The Lancet"},{"key":"pone.0291061.ref038","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.","volume":"396","author":"H-S Kim","year":"2020","journal-title":"The Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:26:41Z","timestamp":1693589201000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291061"}},"subtitle":[],"editor":[{"given":"R. Jay","family":"Widmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0291061","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}